The document outlines a Justification for Non-Competitive Procurement by the Blood Bank Department in NH Guam for specialized supplies and services from Cerus Corporation. Specifically, it seeks to procure INTERCEPT platelet processing sets and annual maintenance services for equipment necessary for blood safety, crucial for preventing transfusion-transmitted infections. The justification indicates that only Cerus Corporation can fulfill these requirements due to their exclusive technology and FDA approvals, which enhance safety standards by reducing microbial contamination risks.
A notice of intent to sole source will be posted on SAM.gov to promote transparency, allowing other suppliers to express interest, even though extensive market research indicated a lack of competitive alternatives due to the highly specialized nature of the products and services. The document emphasizes Cerus Corporation's unique qualifications and exclusive licensing agreements, which support the decision to limit competition. Overall, this procurement process illustrates the government's commitment to ensuring blood safety through advanced technology while adhering to necessary protocols for transparency and competition.
The Department of Defense, specifically the Defense Health Agency Contracting Activity (DHACA), is issuing a Notice of Intent to award a sole source contract to Cerus Corporation for the supply of INTERCEPT Platelet Processing Sets and related maintenance services for the Blood Bank Department at Naval Hospital Guam. This decision is based on the unique capabilities of Cerus Corporation, which specializes in pathogen reduction technology for blood products, significantly enhancing blood safety. The contract period will run from December 1, 2024, to November 30, 2027, with the possibility of two optional extensions. Interested vendors may submit capability statements to demonstrate their qualifications, but this notice does not invite competitive proposals. Responses will help determine if the procurement will proceed as a sole source or competitively. The deadline for any challenges to the requirement is set for November 4, 2024. This notice emphasizes adherence to the Federal Acquisition Regulation and highlights Cerus Corporation's exclusive operating agreements and proven expertise in blood safety solutions.
The Statement of Work (SOW) outlines requirements for implementing pathogen reduction technology at Naval Hospital Guam to enhance blood safety. The Navy Blood Program (NBP), part of the Armed Services Blood Program, seeks to reduce transfusion-transmitted infections and associated complications through FDA-approved systems for platelets and plasma. Key requirements include eliminating the need for bacterial testing, enabling the production of therapeutic doses, and providing comprehensive training and maintenance support from a qualified contractor. Maintenance services must address timely repairs and preventive upkeep, ensuring minimal downtime and compliance with established safety guidelines. The contractor is responsible for using authorized personnel and adhering to confidentiality and warranty provisions while maintaining the equipment's integrity over a 12-month period. This undertaking reflects the federal government's commitment to advancing healthcare standards and safety in blood transfusion practices, aligned with broader initiatives for public health.